Yun Yen , M.D., Ph.D., F.A.C.P.
President and Chief Executive Officer
40+ years in oncology, cancer therapeutics, translational medicine, cancer genomics, academia, philanthropy; 80+ patents (commercialized methodologies in nanoparticles, small/large molecule drugs, biomarkers, stem cells, and medical devices); 400+ peer reviewed publications; Affiliate Professor of Caltech, Case Western Reserve University, Chair Professor Taipei Medical University.
Frank Luh , M.D., M.H.A., M.S.
Executive Vice President
15+ years in Medicine, Cancer Research, Health Care Administration, Drug Discovery; Population Health, and Patient Engagement.
Jeff Masten , MBA
Chief Operating Officer
42 years in Pre-Clinical Toxicology, cGMP Manufacturing, Technical Operations, and Quality for Cell Therapy and Biologic Clinical and Commercial Products.
Global cGMP Regulatory Inspection and agency strategist, host to 13 successful PAI/PLI including the 4th approved commercial CAR T cell therapy.
Chief Financial Officer
28 years in cross boarder banking, venture capital investment, equity research, and corporate executive.
Diverse industry experience in venture capital investment, corporate banking targeting semiconductor, software, and e-commerce.